Zenker, Dieter

[["dc.bibliographiccitation.firstpage","93A"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of the American College of Cardiology"],["dc.bibliographiccitation.lastpage","94A"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Moeller, K."],["dc.contributor.author","Stevens, J."],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Kuehn, R."],["dc.contributor.author","Unterberg, Christina"],["dc.date.accessioned","2018-11-07T10:31:11Z"],["dc.date.available","2018-11-07T10:31:11Z"],["dc.date.issued","2002"],["dc.identifier.isi","000174106700404"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44044"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","0735-1097"],["dc.title","Subthreshold test pulse versus shock delivery to evaluate high voltage impedance in ICD patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1577"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Pacing and Clinical Electrophysiology"],["dc.bibliographiccitation.lastpage","1582"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Stevens, J."],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Krieglstein, H."],["dc.contributor.author","Unterberg, Christina"],["dc.date.accessioned","2018-11-07T09:54:05Z"],["dc.date.available","2018-11-07T09:54:05Z"],["dc.date.issued","2002"],["dc.description.abstract","A small electrode surface reduces pacing current drain and can extend generator longevity. The study evaluated the performance of a tined, quadripolar defibrillation lead (model 6944) that has a small-surfaced, steroid-eluting electrode tip for high impedance pacing. In a prospective, controlled study, 34 patients with conventional ICD indications were randomized one to one to receive the high impedance model 6944 or a tined defibrillation lead with a conventional sized, steroid-eluting electrode tip model 6942. Lead Performance was evaluated at implant, prior to hospital discharge, and 1, 3, 6, and 12 months thereafter. Baseline characteristics did not differ significantly between patients implanted with lead model 6942 (n = 16) or model 6944 (n = 17). One patient randomized to receive the model 6942 was excluded from the study and was implanted with an active-fixation lead after stable lead positioning was neither possible with the 6942 nor with the 6944 electrode. No other lead related adverse events were observed. At implant, there were no significant differences between pacing thresholds, sensing performance, defibrillation impedances, and defibrillation thresholds in both groups, but pacing impedance of the model 6944 (988.6 +/- 217.7 Omega) was approximately twice as high as in the model 6942 (431.7 +/- 83.7 Omega; P < 0.0001). This difference remained highly significant throughout the observation period of 12 months, while R wave amplitudes and pacing thresholds remained equal in both lead models. The use of a tined defibrillation lead with a small, steroid-eluting electrode tip appears safe and results in a high pacing impedance without compromising system performance."],["dc.identifier.doi","10.1046/j.1460-9592.2002.01577.x"],["dc.identifier.isi","000179508100007"],["dc.identifier.pmid","12494614"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36464"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Futura Publ Co"],["dc.relation.issn","0147-8389"],["dc.title","1-Year performance of a defibrillation lead with a small electrode surface for high impedance pacing: A randomized, controlled study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","273"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","280"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Renner, Bernd"],["dc.contributor.author","Kessels, Roger"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Raupach, Tobias"],["dc.contributor.author","Gerritse, Bart"],["dc.contributor.author","Tasci, Selcuk"],["dc.contributor.author","Schwab, Joerg O."],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Schott, Peter"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Unterberg-Buchwald, Christina"],["dc.contributor.author","Andreas, Stefan"],["dc.date.accessioned","2017-09-07T11:47:31Z"],["dc.date.available","2017-09-07T11:47:31Z"],["dc.date.issued","2009"],["dc.description.abstract","Aims The combined therapeutic impact of atrial overdrive pacing (ACIP) and cardiac resynchronization therapy (CRT) on central steep apnoea (CSA) in chronic heart failure (CHF) so far has not been investigated. We aimed to evaluate the effect of CRT alone and CRT + AOP on CSA in CHF patients and to compare the influence of CRT on CHF between CSA positive and CSA negative patients. Methods and results Thirty patients with CRT indication underwent full night polysomnography, echocardiography, exercise testing, and neurohumoral evaluation before and 3 months after CRT implantation. In CSA positive patients (60%), two additional steep studies were conducted after 3 months of CRT, with CRT alone or CRT + ACIP, in random order. Cardiac resynchronization therapy resulted in significant improvements of NYHA class, left ventricular ejection fraction, N-terminal pro-brain natriuretic peptide, VO(2)max, and quality of life irrespective of the presence of CSA. Cardiac resynchronization therapy also reduced the central apnoea-hypopnoea index (AHI) (33.6 +/- 14.3 vs. 23.8 +/- 16.9 h(-1); P < 0.01) and central apnoea index (17.3 +/- 14.1 vs. 10.9 +/- 13.9 h(-1); P < 0.01) without altering steep stages. Cardiac resynchronization therapy with atrial overdrive pacing resulted in a small but significant additional decrease of the central AHI (23.8 +/- 16.9 vs. 21.5 +/- 16.9 h(-1); P < 0.01). Conclusion In this study, CRT significantly improved CSA without altering sleep stages. Cardiac resynchronization therapy with atrial. overdrive pacing resulted in a significant but minor additional improvement of CSA. Positive effects of CRT were irrespective of the presence of CSA."],["dc.identifier.doi","10.1093/eurjhf/hfn042"],["dc.identifier.gro","3143143"],["dc.identifier.isi","000265845700008"],["dc.identifier.pmid","19147446"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/625"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Bakken Research Center, Maastricht, Netherlands"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1388-9842"],["dc.title","Cardiac resynchronization therapy and atrial overdrive pacing for the treatment of central sleep apnoea"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","997"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Heart Rhythm"],["dc.bibliographiccitation.lastpage","999"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Luthje, L."],["dc.contributor.author","Drescher, T."],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Vollmann, Dirk"],["dc.date.accessioned","2018-11-07T10:56:11Z"],["dc.date.available","2018-11-07T10:56:11Z"],["dc.date.issued","2005"],["dc.description.abstract","Decompensated heart failure is the leading cause of hospital admissions for US Medicare patients.(1) Early detection of intrathoracic fluid accumulation may reduce the morbidity and mortality associated with cardiac decompensation, but appropriate tools for monitoring patients with chronic heart failure are lacking. Intrathoracic impedance measurement recently has been integrated in a triple-chamber implantable defibrillator (InSync Sentry (TM), Medtronic Inc., Minneapolis, MN, USA). The system can alert the patient with an audible signal if a decrease in intrathoracic impedance indicates pulmonary fluid accumulation due to cardiac decompensation. However, the clinical value of this monitoring function has not been evaluated. This is the first case report to describe detection of heart failure decompensation using intrathoracic impedance monitoring by an implantable device."],["dc.identifier.doi","10.1016/j.hrthm.2005.06.005"],["dc.identifier.isi","000231986200020"],["dc.identifier.pmid","16171758"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49953"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1547-5271"],["dc.title","Detection of heart failure decompensation using intrathoracic impedance monitoring by a triple-chamber implantable defibrillator"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Contemporary Clinical Trials"],["dc.bibliographiccitation.lastpage","116"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Sohns, Christian"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2017-09-07T11:48:19Z"],["dc.date.available","2017-09-07T11:48:19Z"],["dc.date.issued","2013"],["dc.description.abstract","Aims: The CONNECT-OptiVol study is designed to investigate whether wireless fluid monitoring using OptiVol alerts as well as implantable cardioverter-defibrillator (ICD) remote monitoring (RM) reduces cardiac decompensations and health care utilization in ICD patients, as compared to standard clinical care. Methods: Patients undergoing implantation of wireless telemetry-enabled dual chamber (ICD-DR) or cardiac resynchronization therapy/defibrillator (CRT-D) devices with the OptiVol feature are eligible for the study. In a randomized fashion, OptiVol function, its audible alert as well as its remote alert, and other ICD RM alerts are switched ON or OFF. The primary study objective is to estimate an improvement of heart failure status. The primary endpoint is measured as a prolongation of the time to first hospitalization due to worsened heart failure. The secondary objectives are to estimate: a reduction of the time from event to clinical decision, a reduction of the rate of health care utilization, and improved quality of life (QoL) measures (secondary endpoints). The study is designed as a single center pilot study with 180 patients randomized 1:1 to the two study arms. Conclusion: The CONNECT-OptiVol study aims to answer whether wireless fluid monitoring integrated into RM may reduce cardiac decompensations and health care utilization in ICD patients. The results can be used to adequately power future studies evaluating the benefit of these features. Study enrollment has been completed, and follow-up is expected to be finished in September 2012. (c) 2012 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.cct.2012.10.001"],["dc.identifier.gro","3142414"],["dc.identifier.isi","000314448300014"],["dc.identifier.pmid","23073567"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8019"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1551-7144"],["dc.title","Randomized Clinical evaluatiON of wireless fluid monitoriNg and rEmote ICD managemenT using OptiVol alert-based predefined management to reduce cardiac decompensation and health care utilization: The CONNECT-OptiVol study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1066"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","American Heart Journal"],["dc.bibliographiccitation.lastpage","1070"],["dc.bibliographiccitation.volume","146"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Ahern, T."],["dc.contributor.author","Gerritse, B."],["dc.contributor.author","Canby, R. C."],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Binner, L."],["dc.contributor.author","Kimber, SKM"],["dc.contributor.author","Unterberg, Christina"],["dc.date.accessioned","2018-11-07T10:34:11Z"],["dc.date.available","2018-11-07T10:34:11Z"],["dc.date.issued","2003"],["dc.description.abstract","Background Pacing leads with a small electrode surface for high-impedance stimulation have been shown to prolong pacemaker longevity, but no sufficient data is available on the safety and feasibility of a defibrillation lead with this novel design. Methods We evaluated the clinical performance of a tined, steroid-eluting defibrillation lead with a small electrode surface area (model 6944) in a prospective multicenter study. A total of 542 patients with conventional indications for an implantable cardioverter defibrillator were randomized 1 : 1 to receive either the model 6944 or a tined, steroid-eluting defibrillation lead with a conventional sized electrode surface area (model 6942). Device performance and electrical parameters were evaluated at implant and 1, 3, 6, and 12 months thereafter (mean follow-up 11.3 +/- 5.6 months). Results Baseline characteristics, lead implant success rates, and defibrillation thresholds did not differ significantly between the 2 groups. While pacing thresholds did not differ significantly during follow-up, pacing impedance was approximately twice as high in the model 6944 as in the model 6942 lead (P <.0001). Mean R-wave amplitudes were smaller in patients with a 6944 (9.1 +/- 3.1 mV vs 9.8 +/- 3.6 mV for model 6942, P <.05), but remained stable within both groups throughout the observation period. The total number of ventricular lead-related adverse events and patient survival did not differ significantly between the 2 groups. Conclusions The use of a defibrillation lead with a small electrode surface for high-efficiency pacing is safe and feasible and increases pacing impedance without significantly compromising clinical performance."],["dc.identifier.doi","10.1016/S0002-8703(03)00411-3"],["dc.identifier.isi","187080200025"],["dc.identifier.pmid","14661000"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44798"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mosby, Inc"],["dc.relation.issn","0002-8703"],["dc.title","Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","258"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","EP Europace"],["dc.bibliographiccitation.lastpage","264"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Woronowicz, Sandra"],["dc.contributor.author","Kmiec, Lukasz"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Sossalla, Samuel"],["dc.contributor.author","Dorenkamp, Marc"],["dc.contributor.author","Sohns, Christian"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Zabel, Markus"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2014"],["dc.description.abstract","To evaluate passive-fixation lead failure rates and long-term patient survival in subjects implanted with Sprint Fidelis electrodes. We identified 748 subjects who received a Sprint Fidelis (n 429; Medtronic models 6948: 94.8, 6949: 2.6, 6930: 1.9, 6931: 0.7) or a Sprint non-Fidelis implantable cardioverter defibrillator lead (n 319, Medtronic models 6944: 68.6, 6947: 17.9, 6942: 7.8, 6943: 3.4, 6945: 2.2) at our centre between 1998 and 2008. KaplanMeier patient survival was lower in the Fidelis group than in the Control cohort (68.4 vs. 77.0 at 5 years, P 0.0061), but multivariate analyses revealed no significant association between mortality and implanted lead type. Passive-fixation lead failure rate at 5 years was 14.4 (95 confidence interval (CI) [9.2, 19.3]) in the Fidelis (n 414) group and 1.8 (95 CI [0.03.8]) in the Control (n 241) cohort (P 0.001 upon multivariate comparison). Failure rates of passive-fixation Sprint Fidelis leads are increased and similar to those previously reported for active-fixation Fidelis electrodes. Despite the elevated risk for lead failure and its potential sequelae, the Sprint Fidelis has no obvious impact on long-term mortality."],["dc.identifier.doi","10.1093/europace/eut185"],["dc.identifier.gro","3142190"],["dc.identifier.isi","000331119000018"],["dc.identifier.pmid","23813451"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5532"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Medtronic; Biotronik; Boston Scientific"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1532-2092"],["dc.relation.issn","1099-5129"],["dc.title","Passive-fixation lead failure rates and long-term patient mortality in subjects implanted with Sprint Fidelis electrodes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of the American College of Cardiology"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Unterberg, Christina"],["dc.contributor.author","Stevens, J."],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Krieglstein, H."],["dc.contributor.author","Zenker, Dieter"],["dc.date.accessioned","2018-11-07T09:24:55Z"],["dc.date.available","2018-11-07T09:24:55Z"],["dc.date.issued","2001"],["dc.format.extent","123A"],["dc.identifier.isi","000166914400567"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29945"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","0735-1097"],["dc.title","Randomized comparison between a low and a new high impedance true bipolar defibrillation lead"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1004"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","EP Europace"],["dc.bibliographiccitation.lastpage","1008"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Vollmann, Dirk"],["dc.date.accessioned","2018-11-07T08:54:47Z"],["dc.date.available","2018-11-07T08:54:47Z"],["dc.date.issued","2011"],["dc.description.abstract","Aims A growing number of patients with implanted rhythm devices require new or additional leads, e. g. in cases of electrode defect or planned device upgrade. If the ipsilateral subclavian vein is occluded, transvenous electrode placement from the contralateral side with subcutaneous, pre-sternal lead tunnelling (TUN) is one potential option that has been described in anecdotal reports. The aim of this retrospective study was to determine the acute and long-term feasibility of this approach. Methods and results We identified 18 subjects (67% male, 66 +/- 14 years) who underwent TUN at our institution between the years 1995 and 2009. Implantation protocols and patient files were reviewed for peri-operative complications and long-term lead performance. Furthermore, patients were interviewed for symptoms related to the tunnelled lead. Twenty transvenous leads (seven implantable cardioverter defibrillator leads; five left ventricular, four right ventricular, four right atrial pace/sense electrodes) were successfully tunnelled without significant peri-operative complications. The follow-up duration was 29 +/- 36 (3-162) months. Electrical parameters remained stable in 95% (19/20) of the tunnelled leads. In one right ventricle pace/sense lead, ventricular oversensing was documented 10 months after TUN, and the lead was replaced because a structural defect could not be excluded. Five patients died without causal relationship to the procedure 4-48 months after TUN. One patient reported discomfort related to the tunnelled lead. Conclusion Contralateral transvenous lead implantation with subcutaneous, pre-sternal TUN appears to be a feasible option in selected patients with an implanted rhythm device and ipsilateral subclavian vein occlusion."],["dc.identifier.doi","10.1093/europace/eur072"],["dc.identifier.isi","000292317900018"],["dc.identifier.pmid","21454336"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22750"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1099-5129"],["dc.title","Acute and long-term feasibility of contralateral transvenous lead placement with subcutaneous, pre-sternal tunnelling in patients with chronically implanted rhythm devices"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","716"],["dc.bibliographiccitation.issue","6-7"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","722"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Drescher, Till"],["dc.contributor.author","Schott, Peter"],["dc.contributor.author","Zenker, Dieter"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Unterberg, Christina"],["dc.date.accessioned","2017-09-07T11:49:28Z"],["dc.date.available","2017-09-07T11:49:28Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: An alert algorithm, based on intrathoracic impedance monitoring, has been incorporated into a cardiac resynchronisation device (CRT) to detect pulmonary fluid accumulation, and to audibly alert patients to decompensating chronic heart failure (CHF). Aims: To evaluate this algorithm, alert events were correlated with changes in NT-proBNP concentration and CHF status. Methods and results: In a prospective observational study of 62 patients (89% male, aged 67 +/- 1 year), NT proBNP plasma concentrations, clinical CHF status, and device data were collected at enrolment, during regular follow-up and at device alerts. Over a mean follow-up of 27 +/- 2 weeks, pooled data indicated a weak, but significant inverse relationship between relative changes in intrathoracic impedance and NT proBNP (r=-0.3; p < 0.001). In 52 device alerts from 35 patients, NT proBNP increased by 66 +/- 19% from 2039 +/- 1331 pg/ml (p < 0.001). The increase in NT proBNP was higher in alerts with clinical signs of CHF deterioration (n = 30, 89 +/- 25%;p < 0.001) than in alert events without clinical signs (n = 22, 25 +/- 15%; p = n.s.). Conclusion: Intrathoracic impedance based alert events are associated with a significant increase in NT-proBNP concentration. These data indicate that intrathoracic impedance monitoring might facilitate the outpatient management of CHF patients with implanted CRT devices. 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.ejheart.2007.03.005"],["dc.identifier.gro","3143490"],["dc.identifier.isi","000247148900024"],["dc.identifier.pmid","17462948"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1009"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1388-9842"],["dc.title","Intrathoracic impedance monitoring to detect chronic heart failure deterioration: Relationship to changes in NT proBNP"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]